A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Opicinumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms AFFINITY
  • Sponsors Biogen
  • Most Recent Events

    • 01 Aug 2017 Planned End Date changed from 27 Nov 2020 to 13 Apr 2021.
    • 01 Aug 2017 Planned primary completion date changed from 16 Sep 2020 to 20 Dec 2020.
    • 01 Aug 2017 Planned initiation date changed from 18 Oct 2017 to 28 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top